Key facts
- Ziphius’s last known valuation is $126.1M (Dec 2024).
- It has raised $55.0M; the latest was Later Stage VC ($16.4M) in Dec 2024.
- Notable investors include Annie Vereecken, Christian Dumolin, Jan Haspeslagh.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Ziphius
- ·The full record, as it builds
Funding rounds
No funding rounds for Ziphius are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ziphius
Developer of a biopharmaceutical platform designed to offer vaccines for the prevention of infectious diseases. The company's platform acts as an antigen and initiates a defense mechanism in the body, focusing on self-amplifying RNA-based vaccines for a variety of infectious diseases and protein replacement therapies to rapidly expand the pipeline and move forward multiple preclinical development programs towards the clinic, enabling healthcare providers to reduce the global impact of infectious diseases on global health care.
- Sector
- Healthcare
- HQ
- Gent, Belgium
- Founded
- 2019
- Employees
- 60
- Website
- ziphius.org/
- Ownership
- Privately Held (backing)
Ziphius doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ziphius shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ziphius in its N-PORT filings yet. We sweep new filings monthly.